lygenesis

Organ regeneration using a patient's own lymph nodes

REVOLUTIONARY BIOTECHNOLOGY

LyGenesis, Inc. is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Our initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).

disrupting organ transplantation

Instead of one donor organ treating one patient, LyGenesis enables one donor organ to treat dozens of patients.

Instead of major surgery, LyGenesis uses outpatient endoscopy for transplantation of donor cells, which grow and become a functioning ectopic organ.

Our pipeline

A decade age, Dr. Eric Lagasse, a world leader in ectopic transplantation research, began a series of experiments that would form the foundation for LyGenesis. He discovered that hepatocytes (liver cells) transplanted into lymph nodes would not just survive, but thrive, organize and begin to function as miniature ectopic livers. His research, published in Nature BioTechnology, Current Opinions in Organ Transplantation, and elsewhere confirms that it is possible to harness the body's lymph nodes as bioreactors for organ regeneration.

NEWS

A University of Pittsburgh spin out company offers a remarkable prospect for people with a disease-ridden liver: a way to make a new liver.

Like something from a science fiction novel, LyGenesis Inc. claims to have come up with a way to create working liver tissue in patients whose organs have been destroyed by disease. Investors are feeling the buzz.

Lagasse said there are about 20,000 people waiting for liver transplants, which represents only a fraction of people suffering from liver disease who could benefit from the treatment. Depending on the stage of the disease, ectopic liver generation treatment could serve as a bridge to a transplant, or if done early enough in the disease progression, eliminate the eventual need for a transplant.